Philips Launches AI-Powered SmartSpeed Precise MRI Software at ECR
The updated software reportedly enables a threefold improvement in MRI scan time and enhanced image sharpness.
Philips has unveiled SmartSpeed Precise, an artificial intelligence (AI) software that may significantly bolster scan times and image sharpness with MRI scans.
Launched at the European Congress of Radiology (ECR) conference, the SmartSpeed Precise software allows up to a threefold reduction in MRI scan times, according to Philips.
Here one can see a pelvic MRI with use of the SmartSpeed Precise technology on a Philips Ingenia Evolution MR 3T scanner. The SmartSpeed Precise software, which is being launched at the European Congress of Radiology (ECR) conference, reportedly facilitates an 80 percent improvement in image sharpness on MRI. (Image courtesy of Philips.)
Incorporating the company’s Compressed SENSE and SmartSpeed technologies, Philips said the next-generation SmartSpeed Precise software facilitates detection of subtle abnormalities with an 80 percent improvement in image sharpness.
“We are impressed by the extremely sharp and crisp images, diagnostic confidence, and fast scans delivered by the dual-AI SmartSpeed Precise solution. We expect it will set a new standard in clinical performance with its ease of use, high image quality, and acceleration controlled by a single parameter,” noted Wayne Picker, a vice president of clinical technology at Prenuvo, Inc.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
